Whereas many people with serious, chronic mental illness, such as schizophrenia and other schizoaffective disorders, bipolar disorder, or severe depression, require treatment with medications that work as dopamine receptor blocking agents (referred to in this preamble as DRBAs ), including antipsychotics; Whereas, while ongoing treatment with DRBAs can be very helpful, and even lifesaving, for many people it can also lead to tardive dyskinesia; Whereas many people who have gastrointestinal disorders, including gastroparesis, nausea, and vomiting, also require treatment with DRBAs; Whereas treatment of gastrointestinal disorders with DRBAs can be very helpful, but for many patients can lead to tardive dyskinesia; Whereas tardive dyskinesia is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities; Whereas, in some cases, tardive dyskinesia may— (1) cause people to experience movement of the arms, legs, fingers, and toes; (2) affect the tongue, lips, and jaw; and (3) cause swaying movements of the trunk or hips and impact the muscles associated with walking, speech, eating, and breathing; Whereas tardive dyskinesia can develop months, years, or decades after a person starts taking DRBAs and even after they have discontinued use of those medications; Whereas not everyone who takes a DRBA develops tardive dyskinesia, but if tardive dyskinesia develops, it is often permanent; Whereas common risk factors for tardive dyskinesia include advanced age and alcoholism or other substance abuse disorders; Whereas postmenopausal women and people with a mood disorder are also at higher risk of developing tardive dyskinesia; Whereas a person is at higher risk for tardive dyskinesia after taking DRBAs for 3 months or longer, but the longer the person is on these medications, the higher the risk of developing tardive dyskinesia